A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Sponsor
Hoffmann-La Roche
Study ID
NCT06267001
Phase
PHASE3
Status
Completed

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Atezolizumab will be administered IV.
  • Tiragolumab — DRUG
    Tiragolumab will be administered IV.
  • Placebo — DRUG
    Placebo will be administered IV.

Study Details

The purpose of this study was to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered to participants with non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy.

Key Dates

Start date
Mar 21, 2024
Status verified
Feb 2026
Primary completion
Dec 16, 2025
Completion
Dec 16, 2025

Study Design

Enrollment
56 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab + Tiragolumab
    Participants will receive atezolizumab and tiragolumab intravenously (IV).
  • Placebo Comparator: Atezolizumab + Placebo
    Participants will receive atezolizumab and placebo IV.

Primary Outcome Measure

Percentage of Participants With Adverse Events (AEs) [ Time Frame: Up to approximately 2 years ]

Related coverage on Hipa.ai

Related Studies